As per this study the global epigenetics drugs and diagnostic technologies market was valued USD XX MN (by revenue) in 2021 and is anticipated to reach USD XX MN by 2028 with a CAGR of XX%.
Epigenetics is a study of heritable changes in gene expression, it’s a change in phenotype without a change in genotype. Epigenetics drugs and diagnostic is used in screening of early stage cancer and other abnormal changes in skin cells, liver cells, brain cells, and others. It is caused by various factors such as aging and lifestyle changes along with environmental exposures.
The increasing geriatric population and rising oncology and non-oncology disorders are driving the market growth. Also, the high prevalence of cancer with advancement is screening techniques is further fuelling market growth. In addition, reduction in sequential cost and time is another factor pushing the market growth. Though, the funding and support of the organizations such as NIH and NCI for R&D are expected to boost the market growth in the forecast period. However, problems associated with quality may hamper market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of epigenetics drugs and diagnostic technologies.
The broad epigenetics drugs and diagnostic technologies market has been sub-grouped into drugs mechanism of action and technology type. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Drugs Mechanism Of Action
By Technology Types
- DNMT Inhibitors
- Azacitidine (Vidaza)
- Decitabine (Dacogen)
- HDAC Inhibitors
- Vorinostat (Zolinza)
- Romidepsin (Istodax)
- DNA Methylation
- Chromatin Immunoprecipitation (ChIP) Technology
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for epigenetics drugs and diagnostic technologies in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Global Epigenetics Drugs And Diagnostic Technologies Market Share by Region (Representative Graph)
The report also covers a detailed competitive landscape including company profiles of key players operating in the global market. The key players in the epigenetics drugs and diagnostic technologies market include 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celleron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, EnVivo Pharmaceuticals Inc., Epigentek Group Inc., Epizyme, Inc. Illumina Inc., MDxHealth, Merck, Merck & Company Inc., Novartis International AG, Oncolys BioPharma Inc., Pharmacyclics, Promega Corporation, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Inc., Topotarget A/S, and Valirx Plc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.